.H...A.....M.[00.\...\01.^.O.Z

untitled

28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS

Graminex社の”花粉エキスG63”による前立腺炎への知見

Graminex G63 IPSS Graminex Graminex G60 GFX 1 3 1 mg 62.5mg 66.1 5.7 17 29 Graminex G63 ED ED ED ED G63 IIEF5 G Graminex Graminex G60 GFX 1 3 1 mg 62.5mg 9 69.2 3 23.1 1 7.7 1 ED 1 1 2005.10.14 Graminex

19 8 1970 20 10 4 1

19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE

CAT.No. 1234

01p_86.._......

JAPAN WASTE MANAGEMENT & 3Rs RESEARCH FOUNDATION 3Rs Promotion Forum 20141 HH H HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH

62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -

1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /

公　　 民　［　倫 理　］　（100点　50分）

100 50 2004 5 24 2 3 1,2,3,4,6,7,8,9 Produced by K.Kataoka 1.2.3 1 1 50 ( ) 250 485 ( to hen) 6 1000 1 ( (a) ) 2 nous (b) (c) (d) chaskein( ) 1 ( ) (e) 1 2 3 3 (a) 4 (b) 5 (c) ~ 2004 6 (d) 7 4 10 49 (e)

橡魅力ある数学教材を考えよう.PDF

Web 0 2 2_1 x y f x y f f 2_2 2 1 2_3 m n AB A'B' x m n 2 1 ( ) 2_4 1883 5 6 2 2_5 2 9 10 2 1 1 1 3 3_1 2 2 2 16 2 1 0 1 2 2 4 =16 0 31 32 1 2 0 31 3_2 2 3_3 3_4 1 1 GO 3 3_5 2 5 9 A 2 6 10 B 3 7 11 C

untitled

619-2009/02/21 21:03-9 30 3 8 7 5.0 6.2 618-2009/02/21 19:54-12 6 15 10 15 617-2009/02/21 19:22 - http://picasaweb.google.com/oda5279/2009022156# 615-2009/02/21 08:54-614 - 2009/02/21 07:24-9 10 5 613-2009/02/21

a n a n ( ) (1) a m a n = a m+n (2) (a m ) n = a mn (3) (ab) n = a n b n (4) a m a n = a m n ( m > n ) m n 4 ( ) 552

3 3.0 a n a n ( ) () a m a n = a m+n () (a m ) n = a mn (3) (ab) n = a n b n (4) a m a n = a m n ( m > n ) m n 4 ( ) 55 3. (n ) a n n a n a n 3 4 = 8 8 3 ( 3) 4 = 8 3 8 ( ) ( ) 3 = 8 8 ( ) 3 n n 4 n n

4. :,,, :p , :, :p (141/204//S, 141.5/2//W) 5.,,, :p (141.5/5//W) 6. : 21,,, : (141/208//S, 141.5/4//W) 7. 1,,19

5 (1997 ),,,,, ( ) 1 1. :,,1997.4 :p201-205 (401/943//S, 401/570//W) 2. :,,1997.7 : p5-18 (141.5/67//H, 141/547//W) 3. : J,,,,,1998.6 : p17-39 (141.5/72//H) 4. :,,,1999.2 :p210-224, :, :p206-209 (141/204//S,

A R & B A % % z z z z c c z A B c C jc jc LC LC R s A c c & zz % & & A A c c B & % & A R B z z z A B c c c c c c c c A B A B c C c c D A % B z z c j c z z A c B c z A % B c cc cc cc % % z c c z c cc 19

さくらの個別指導 ( さくら教育研究所 ) a a n n A m n 1 a m a n = a m+n 2 (a m ) n = a mn 3 (ab) n = a n b n a n n = = 3 2, = 3 2+

5 5. 5.. a a n n A m n a m a n = a m+n (a m ) n = a mn 3 (ab) n = a n b n a n n 0 3 3 0 = 3 +0 = 3, 3 3 = 3 +( ) = 3 0 3 0 3 3 0 = 3 3 =, 3 = 30 3 = 3 0 a 0 a`n a 0 n a 0 = a`n = a n a` = a 83 84 5 5.

2004 12 2004 10 23 11 19 23 5 2004/11/18 2004/11/19 2004/11/20 2004/11/21 2004/11/22 2004/1/23 2004/1/24 2004 12 1 www.gsi.go.jp/bousai/niigatajisin/jyoukyouzu/5man1029-1500.pdf 2 2004 10 23 5 56 3717.3'N

1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF

2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR

Introduction

CH1~4 OSD,HDD OSD HDD CH4 CH3 CH2 CH1 HDD ADMIN ID &, IP,,, DNS, ID,,DDNS DDNS,, E- E-,, IP RS-485/422 M/D ID,,,, CH1~4, CH1~4 1~4 PTZ CH1 PTZ ID, CH2 PTZ ID, CH3 PTZ ID CH4 PTZ ID PTZ

（印刷）分身主義の森を抜けて‥‥

2 !? 3 Bunshinism Bunshinism Bunshinism 4 P178 P180 5 *1 *1 *2 *2 ( ) P122!? P37 6 > > > ( ) 7 -------------------- -------------------- 8 P54 9 P180 10 > > > etc. 11 P30 P128!? P216 12 () 13 *3 *3 14

›Ê”÷„¤‰ƒ‘−…j…–†[…X

ISSN 1347-0345 National Institute of Fruit Tree Science 2003. 10 2 2003. 10 3 19761986 1989 5219 1997 19 12 10 250 270g Brix 15 160.5g/100ml 1590 10 2003. 10 4 DNA DNASSR 44 41SSR SSR Simple Sequence Repeat=

dp0206_j

1 2 7 8 9 4 5 6 3 10 11 12 13 20 19 18 16 17 15 14 CONTROL AUDIO 2 AUDIO 1 CN2 CN1 CN20 CN15 1 2 3 4 H C E (E) 1 2 3 E C H 1 2 3 4 C 8 7 6 5 6 7 8 9 5 4 3 2 1 E A B SIGNAL/

(1) 3 (2) (3) (5) (7) (1) 65P00010 (4) (6) 81M00020 1 2 3 4 1-2 1-16 1-22 2-2 3-2 3-17 3-20 3-24 3-30 3-39 3-45 3-53 3-63 3-105 4-2 4-12 4-14 4-24 4-29 5 6 7 8 9 4-38 4-71 4-73 5-2 5-22 5-33 6-2 6-9

鼻副鼻腔疾患に伴う頭痛，顔面痛

118 833 : VV CT : Sluder CT CT VV V V V 118 834 2015 1 V V V V Sluder neuralgia Sluder Sluder Sluder neuralgia V C2 4 CT MRI CT CT CT OM V V V V 118 835 a b c d e f g h 1 CT : : : : : : 118 836 2015 a

Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS

RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD

. R R D e R R 7 () r r R R () l t t R R 7 l () () R r rr r r n r n r r 3 6 r 88 R r 360 r = e t t = e r t rt rt, r t, r 3 t, r t R R R R R D = {e, r,

3 3 3 e X X X X X X . R R D e R R 7 () r r R R () l t t R R 7 l () () R r rr r r n r n r r 3 6 r 88 R r 360 r = e t t = e r t rt rt, r t, r 3 t, r t R R R R R D = {e, r, r, r 3, r, t, rt, r t, r 3 t, r

untitled

5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm

転がり軸受　総合カタログ

K 4 21 AU L TDO TD 10500 mm 1 10220 mm 10130 mm 19 mm 19 mm 1075 mm 4 5 1 ZZ 2RU 2RS 2RK 2RD JIS 1512 ML JIS 1514-1 A60 A63 7-3 JIS 1520 A102 10-2 A102 10-3 A105 10-7 ZZ 2RU (a) 1) (b) (c) (d) 2) (e) (f)

(1) 3 (2) (3) (5) (7) (1) 65P00010 (4) (6) 81M00020 1 2 3 4 1-2 1-16 1-22 2-2 3-2 3-17 3-20 3-24 3-30 3-39 3-45 3-53 3-63 3-104 4-2 4-12 4-14 4-26 4-29 5 6 7 8 9 4-34 4-43 4-64 4-67 5-2 5-22 5-34 6-2

bell_37中間_1121.indd

Interim Business Report 37 24 4 124 9 3 33 34 35 2 2 2 2 2 2 9 21 3 21 9 22 3 22 9 23 3 23 9 24 3 24 9 54,646 19,912 46,8 1,11 46,822 13,46 49,754 11,3 54,242 2,236 2,239 1,659 4,267 2,45 6,364 1,934 7,151

薬局におけるインシデント事例の集計･分析結果

13 11 14 31 13 11 14 31 13 11 14 31 10 13 13 e-mail 18 4,000 13 14 H13.4.1 11.17 11.18 H14.3.31 13 14 31-1- 600 400 (18.4 17.7 17.0 16.0 15.2 8.2 1.0 2 11 10 12 15 3 1015203040 69.5 7.8 22.7 4 (42.5) 34.3

A R B & z z z z A % c c z

A R B & z z z z A % c c z % A B c C jcj c LC LC R A c c & z % & & A R B z z z A B c c c c c A B A B c C c c D c c c A % B % c j c z z A c B c A % B c cc cc cc % % z c c z cc A B c 19 c % A & B A B cc v

広島県獣医学会雑誌24号.indd

1 1 Study on the effects of dexamethasone administration in acute coccidiosis accompanied by bloody stools TOMOYASU KUROSE Shoubara Veterinary Clinical Center, P. F. A. M. A. A -1-, Nishihonmachi, Shoubara,

1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105

異常に起因する紫斑病 2) 小児に多く成人には比較的まれ 1) 本症の紫斑の特徴は手に触れる紫斑 palpable purpura で発熱 関節痛を伴いながら 主として四肢 顔面 躯幹に現れ 特に四肢では関節部に多く 丘疹状紅斑でその中心部から出血がみられることである 1) 本症に特徴的な紫斑は 1

ヘノッホ シェーンライン紫斑病 (Henoch-Schonlein purpura:hsp)(101129) 小児の診察で 下腿に紫斑を見たら想起するようにと教わった疾患 一度復習が必要 本症の病態は血管のアレルギーにより透過性が亢進し紫斑を生ずるもので lga や免疫複合体の関与が考えられている 1) 一般には上気道感染 溶連菌性咽頭炎が先行し 感染症が軽快して 1~3 週間後に紫斑が発現する また食物や薬物アレルギーが原因となる場合もある

橡DI月報１７8.PDF

2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19

好酸球性副鼻腔炎:診断ガイドライン（JESREC Study）

118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc

6 2 2 x y x y t P P = P t P = I P P P ( ) ( ) ,, ( ) ( ) cos θ sin θ cos θ sin θ, sin θ cos θ sin θ cos θ y x θ x θ P

6 x x 6.1 t P P = P t P = I P P P 1 0 1 0,, 0 1 0 1 cos θ sin θ cos θ sin θ, sin θ cos θ sin θ cos θ x θ x θ P x P x, P ) = t P x)p ) = t x t P P ) = t x = x, ) 6.1) x = Figure 6.1 Px = x, P=, θ = θ P